Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis' Scemblix
默沙东将以67亿美元收购Terns，纳入一款有望挑战诺华Scemblix的白血病药物

Merck is looking to further solidify its oncology pipeline via a $6.7 billion cash acquisition of Terns Pharmaceuticals and its investigational treatment for chronic myeloid leukemia.
默沙东正寻求通过一笔67亿美元的现金收购，进一步巩固其肿瘤学管线，收购对象为Terns Pharmaceuticals及其用于治疗慢性髓性白血病的在研疗法。